R&D Boosting clinical trial productivity to prove Eroom wrong According to Eroom’s law, drug discovery becomes slower and costlier over time. And the data are, at least in part, bearing that out.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
